



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostics.com

Date: August 25, 2025

To,

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Ref: Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Trading Symbol: CHANDAN, ISIN: INE0B2N01016

Sub: Presentation of Investor Meeting with Alpha Ideas SME Stars 2025 Edition held on August 24, 2025

Dear Sir/Madam,

We hereby submit the enclosed presentation of the investor meeting held with **Alpha Ideas SME Stars 2025 Edition** on Sunday, August 24, 2025.

Further, in compliance with Regulation 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the aforesaid presentation has also been made available on the Company's website at the following link:

<https://chandandiagnostics.com/admin/uploads/Final%20Presentation.pdf>

You are requested to kindly take the above information on record.

Yours sincerely,

For Chandan Healthcare Limited

Rajeev Kumar Nain

Company Secretary & Compliance Officer



Chandan Healthcare Limited

Investor Presentation

Disclaimer



This presentation and the accompanying slides (the Presentation), which have been prepared by **Chandan Healthcare (Chandan, The Company)** solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks.

The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



Company Overview

Redefining Diagnostics & Pharmacy in North India

Chandan at a Glance



Chandan Healthcare Limited is one of the leading North India-based providers of diagnostic and pharmacy services, and a key entity within the Chandan Group. The Company offers a comprehensive suite of NABL/NABH-accredited pathology and radiology solutions across Uttar Pradesh and Uttarakhand.

Its service portfolio includes a wide range of diagnostic tests such as blood tests, X-ray, ECG, ultrasound, CT scan, MRI, and other specialized investigations, ensuring reliable and high-quality care.

Chandan operates through a diverse business model spanning B2C (retail customers), B2B (institutional partnerships), and B2G (government PPP contracts) all under a company-owned model that guarantees consistent standards and operational control.


To capture rising demand across urban and semi-urban markets, Chandan is actively expanding into neighboring states including Delhi, Rajasthan, Bihar, Chhattisgarh, and Madhya Pradesh, with a strategic focus on metro hubs and Tier 2/3 cities.

The company got listed on NSE Emerge on 17th February 2025





CHANDAN GROUP OF COMPANIES



Key Facts & Figures



20+
years of industry
expertise



1,496 +
Pathology Tests
Offered



481 +
Radiology Tests
Offered



FY25
Revenue: ₹ 232.17 Cr
EBITDA: ₹ 43.38 Cr
PAT: ₹ 22.17 Cr



1300+
Team Size



18.21 lakh
Total Patient Count
(FY25)



360
Collection Centres



53.98 lakh +
Total Test
Conducted(FY25)



40
Diagnostic Centres



**NABH MIS
Accreditation**
for 5 centres




35 Cities
Across
4 states
Presence



**NABL
Accreditation**
For 10 Labs



Key Events & Achievements



+ Board Of Directors



Amar Singh

Promoter, Chairman and Managing Director

MBBS with 20+ years of experience in the healthcare industry



Asmita Singh

Promoter and Managing Director

BBA and MBA with 20+ years of marketing experience



Vinay Lamba

Non-Executive Director

Marine Engineer with 10+ years of experience in technical operations & equipment strategy



Amit Gupta

Non Executive Independent Director

B.Sc. and FCS with 20+ years of experience in corporate compliance and secretarial practice.



Brahma Nand Bhartiya

Non Executive Independent Director

B.A., M.A. with experience in labour administration; retired Assistant Labour Commissioner, UP.



Vinod Jain

Independent Director

MS (General Surgery) with fellowships from ACS and ICS.

Awards & Accolades



Most Innovative Healthcare Service Provider, 2018



ET Leadership Excellence Award-2024



Pride of India Awards Best Employer Brand 2018



India's Most Prominent Women Empowerment Awards 2019.





Business Overview

Multi-Segment Model Driving Growth Across B2C, B2B & B2G

Diversified revenue streams ensure stability, scalability, and reduced risk.



B2C (Retail Diagnostics)

- Walk-in services across **35+ cities & 4 states**
- **18L+ patients served** in FY25
- Strong brand recall, reliable service, affordable care

FY25 Revenue

₹86.35 Cr
(37.53%)



B2B (Institutional Clients)

- **230+ private hospitals & clinics** as partners
- Recurring, long-term relationships
- Steady revenue from integrated tie-ups

FY25 Revenue

₹91.30 Cr
(39.68%)



B2G (Government PPPs)

- Public-Private Partnerships with **state governments**
- Diagnostic services in government hospitals
- Long-term contracts ensure stable cash flow & credibility

FY25 Revenue

₹52.45 Cr
(22.80%)



Pathology
FY25 Revenue
₹135.24 Cr
(41.93%)



Radiology
FY25 Revenue
₹ 52.45 Cr
(12.08%)



Pharmacy
FY25 Revenue
₹ 105.80 Cr
(45.99%)

State of the Art Pathology Laboratory




Pathology



Radiology



Chandan's Centre Network – Scale & Differentiation



Top Performing Centres Across Categories



Large
Ayodhya, Rikabganj
Revenue – ₹ 8.43 Cr
Customers Served – 85,904



Medium
Lucknow, Indira Nagar
Revenue – ₹ 8.98 Cr
Customers Served – 55,001



Small
Haldwani, Nainital Road
Revenue – ₹ 2.36 Cr
Customers Served – 25,324

Indian Diagnostics Sector Overview



Market Size & Growth

- Diagnostics industry expected to grow from US\$13 Billion (FY23) to US\$25 Billion (FY28) at a 14% CAGR.
- Growth driven by rising chronic diseases, ageing population, demand for preventive tests, and wider insurance coverage

Pathology Segment

- Accounts for 58% of the diagnostics market, currently valued at US\$7.5 Billion, projected to reach US\$14.4 Billion by FY28.
- India has ~1.32 lakh pathology labs, with 60%+ operating as standalone centres

Radiology Segment

- Comprises soft (X-ray, ultrasound) and advanced (CT, MRI, nuclear imaging).
- Market projected to reach US\$11 Billion by FY28, with growth led by demand in Tier 2/3 cities and advanced diagnostics.
- India has 55,000+ radiology labs, over 80% of which are standalone.


Market Structure & Opportunities

- Highly fragmented: 46% standalone, 28% private hospital labs, and 6% national chains.
- Low test prices vs developed countries indicate room for price realisation and margin expansion.
- Fragmentation opens scope for consolidation and scalable models.

Healthcare Infrastructure Gap

- India faces a shortfall of 3 million hospital beds, underscoring the urgent need for capacity expansion across healthcare and diagnostics.

Indian Diagnostic Market (US\$ Billion)



From illness detection to preventive care diagnostics is entering a new era. (Highlight this)

Source: [Businessline](#)

Investor Presentation

Key Strengths Driving Sustainable Growth



Expanding Footprint Across North & Central India



Upcoming Cities	Tentative month
Delhi	Sep -25
Bhopal	Sep -25
Raipur	Oct -25
Bareilly	Nov-25
Noida	Jan -26
Meerut	Feb -26
Ghaziabad	Mar-26

Targeting high-growth Tier-2/3 and suburban markets

Chandan Healthcare is expanding into six key cities across North and Central India, focusing on regions with growing demand for integrated diagnostics services.

Expansion Highlights



- **New States:** Entry into **Delhi, Madhya Pradesh & Chhattisgarh**
- **Strengthening Presence:** Deepening network in **Uttar Pradesh & Uttrakhand**
- **Strategic Focus:** Addressing **diagnostic gaps** in mid-sized cities & suburban regions

26

Growth via Chandan Medical Centres(CMC)



- Plan to open **20+ new CMCs annually** under structured, long-term strategy
- Expanding **affordable, quality diagnostics** across underserved regions
- Delivering **integrated healthcare services** close to **communities**



Financial Overview

Consistent Growth Backed by Scale, Efficiency & Expansion

Year On Year Revenue Growth

30.57%

Fixed Asset Turnover

2.86 Times

Interest Coverage

7.95 Times

Return on Equity

27.08%

Year on Year Profit Growth

36.17%

Return on capital Employed

29.34%

Debt to Equity

0.39 Times




Book Value

₹ 50.14

Key Financial Highlights



(All Amount In ₹ Cr & Margins In %)



The Company demonstrated exceptional financial growth over FY23 to FY25. Revenue increased by 69.43%, rising from ₹137.03 Cr to 232.17 Cr, reflecting strong business expansion. EBITDA surged by 355.67%, from ₹9.52Cr to ₹43.88 Cr, driven by improved operating leverage and cost efficiencies. PAT rose by 557.86%, from ₹3.59Cr to ₹22.17Cr, indicating sharp gains in profitability and bottom-line strength.

Profit & Loss Statement



(In ₹ Cr)

Particulars	FY23	FY24	FY25
Revenues	136.89	176.59	230.12
Other Income	0.14	1.2 2	2.0 5
Total Income	137.03	177.81	232.17
Raw Material Expenses	64.71	80.85	107.62
Employee Costs	25.49	35.42	38.86
Other Expenses	37.30	33.92	42.31
Total Expenditure	127.51	150.19	188.79
EBITDA	9.52	27.62	43.38
EBITDA Margin	6.95%	15.53%	18.69%
Finance Costs	2.42	2.75	4.58
Depreciation	2.09	3.40	6.74
PBT	5.01	21.46	32.06
Tax	1.43	5.11	8.55
Minority Interest	0.22	0.08	1.34
PAT	3.36	16.27	22.17
PAT Margin	2.46%	9.22%	9.63%

Balance Sheet






(In ₹ Cr)



Equities & Liabilities	FY23	FY24	FY25
Equity	20.00	20.00	24.45
Reserves And Surplus	2.76	21.16	98.15
Total Equity	22.76	41.16	122.60
Non-Current Liabilities			
Long Term Borrowings	7.89	12.18	22.14
Other Long-TermLiabilities	-	-	-
Long Term Provision	1.39	1.39	1.72
Deferred Tax Liabilities	2.19	3.06	3.46
Total Non-Current Liabilities	11.48	16.63	27.33
Current Liabilities			
Short Term Borrowings	13.46	23.74	26.02
Trade Payables	34.94	19.51	25.78
Short Term Provisions	0.51	0.35	0.69
Other Current Liabilities	7.68	14.23	4.39
Total Current Liabilities	56.60	57.82	56.88
Total Equity & Liabilities	98.13	118.07	210.62

Assets	FY23	FY24	FY25
Non-Current Assets			
Fixed assets	32.56	48.49	80.45
Non-Current Investments	4.54	3.38	1.15
Other Non Current Financial Assets	-	-	-
Other Non Current Assets	3.55	3.67	18.17
Total Non-Current Assets	44.58	56.74	100.31
Current Assets			
Inventories	9.87	18.24	31.37
Trade Receivables	23.69	28.61	46.70
Cash & Bank Balance	2.04	3.90	6.21
Other Current Assets	3.04	2.36	16.43
Other Current Financial Assets	14.91	8.22	9.60
Total Current Assets	53.55	61.33	110.31
Total Assets	98.13	118.07	210.62

+ Key Ratios





+ Key Ratios




As On 21-08-2025

As On 31-03-2025

NSE (SSEGL INE0RFP01011)	
Share Price (₹)	238.00
Market Capitalization (₹ Cr)	581.96
No. of Shares Outstanding	2,44,52,064
Face Value (₹)	10.00
52-week High-Low (₹)	279.00 – 140.00





Thank You



Address: Chandan Healthcare Ltd. Biotech Park,
Kursi Road, Lucknow 22602 | U.P.

Email: care@chandan.co.in

Phone: 08069366666

Website: www.chandandiagnostic.com

Dr. Amar Singh
(Chairman and MD)

Mr. Rajeev Nain
(Chief Financial Officer)

